4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DMEGlobeNewsWire • 05/12/21
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution PlatformGlobeNewsWire • 05/04/21
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care ConferenceGlobeNewsWire • 04/30/21
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate StudiesGlobeNewsWire • 04/27/21
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational HighlightsGlobeNewsWire • 03/25/21
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry DiseaseGlobeNewsWire • 03/09/21